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Abbreviations 
4E-BP, eIF4E binding protein; CDK, cyclin-dependent kinase; CRC, colorectal cancer; 
eIF4E, eukaryotic translation initiation factor 4E; Erk, extracellular signal-regulated kinase; 
HCCLs, human colon cancer cell lines; IC50, half-maximal inhibitory concentration; IP, 
Intraperitoneal injection; JC-1, 5,5’,6,6’-tetrachloro-1,1’3,3’-
tetraethylbenzimidazolylcarbocyanine iodide; MAPK, mitogen-activated protein kinase; 
MMP, mitochondrial membrane potential; KD, knockdown; Mnk, mitogen-activated protein 
kinase-interacting kinase; mTOR, mammalian target of rapamycin; PO, oral dosing; PARP, 
poly (ADP-ribose) polymerase; PI, propidium iodide; Q3D, once every 3 days dosing; Q7D, 
once a week dosing; p-RNAPII
S2
, phosphorylated RNAPII serine 2;  RNAPII, RNA 
polymerase II; rpS6, ribosomal protein S6; RT-qPCR, real time-quantitative polymerase 
chain reaction; shRNA, short hairpin RNA; XIAP, X-linked inhibitor of apoptosis 
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Abstract 
Colorectal cancer (CRC) remains one of the most lethal human malignancies and pursuit of 
new therapeutic targets for treatment has been a major research focus. Cyclin-dependent 
kinase 9 (CDK9), which plays a crucial role in transcription, has emerged as a target for 
cancer treatment. CDKI-73, one of the most potent and pharmacologically superior CDK9 
inhibitors, has demonstrated excellent anti-tumor efficacy against several types of cancers. In 
this study, we evaluated its therapeutic potential against CRC. CDKI-73 elicited high 
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cytotoxicity against all colon cancer cell lines tested. Cell cycle and apoptosis analysis in 
HCT 116 and HT29 cells revealed that CDKI-73 induced cell death without accumulation of 
DNA at any phase of the cell cycle. Moreover, it caused depolarisation of mitochondrial 
membrane leading to caspase-independent apoptosis. Knockdown by shRNA demonstrated 
the CDK9 targeted mechanism of CDKI-73, which also affected the Mnk/eIF4E signalling 
axis. In addition, RT-qPCR analysis showed that CDKI-73 downregulated multiple pro-
survival factors at the mRNA level. Its in vivo anti-tumor efficacy was further evaluated in 
Balb/c nude mice bearing HCT 116 xenograft tumors. CDKI-73 significantly inhibited tumor 
growth (***p < 0.001) without overt toxicity. Analysis of the tumor tissues collected from 
the xenografted animals confirmed that the in vivo anti-tumor efficacy was associated with 
CDK9 targeting of CDKI-73. Overall, this study provides compelling evidence that CDKI-73 
is a promising drug candidate for treating colorectal cancer.  
 
1.  Introduction 
Colorectal cancer (CRC) is one of the most lethal malignant neoplasms worldwide. It shows 
substantial genetic heterogeneity and aberration in multiple cellular pathways among the 
subtypes (Hahn et al., 2016). Clinical, morphological and molecular features of CRC assisted 
to create a defined classification of the disease subtypes, facilitating the prospect of 
personalized treatment for CRC patients. Despite the availability of defined classification of 
the disease subtypes and immense improvement in systemic therapy, not all the subtypes are 
susceptible to currently available treatments. Moreover, in metastatic incurable form of CRC, 
treatment with cytotoxic chemotherapy is able to achieve 5 year survival rate only in 12.5% 
of the patients (Siegel et al., 2014). On the other hand, targeted therapies like cetuximab or 
panitumumab as monotherapy have very low response rates of 10% to 20% and ultimately 
progression of disease occurs due to resistance (Bardelli and Siena, 2010; Cunningham et al., 
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2004). Development of resistance to cytotoxic (e.g. Fluoropyrimidines) and targeted therapies 
(e.g. EGFR targeted therapies cetuximab or panitumumab) remains the primary reason for 
treatment failure. Thus, development of new therapeutic targets that can translate into better 
clinical outcomes is urgently needed for CRC patients. 
Cyclin-dependent kinase 9 (CDK9) is such a potential target for the treatment of CRC 
which plays a crucial role in the elongation step of global transcription process. Multiple 
studies using small molecule inhibitors and RNA interference have demonstrated that 
oncogenic transcription driven by CDK9 increases the survival and proliferation of cancer 
cells (Chen et al., 2005; Huang et al., 2014) and hence continuously targeted for cancer 
treatment (Baker et al., 2016; Morales and Giordano, 2016; Rahaman et al., 2016). Since 
CDK9 plays such a critical role in the transcription of a number of oncogenes (Krystof et al., 
2012; Lam et al., 2001; Wang and Fischer, 2008), targeting CDK9 may provide a promising 
therapeutic strategy for the treatment of CRC. 
CDKI-73 is a highly potent small molecule inhibitor of CDK9 (Lam et al., 2014; Shao 
et al., 2013). It demonstrated potent cytotoxic effects on a wide range of cancer cell lines 
from different origins, but proved to be less toxic towards normal cells (Lam et al., 2014; 
Walsby et al., 2014). CDKI-73 also demonstrated a synergistic effect with fludarabine 
through a mechanism associated with the transcriptional inhibition of multiple anti-apoptotic 
proteins like Mcl-1, Bcl-2 and XIAP which represented a promising therapeutic strategy for 
treating CLL and fludarabine-relapsed diseases. Moreover, recent knockdown studies in 
A2780 ovarian cancer cells revealed that the downregulation of CDK9 affected the oncogenic 
translation via the Mnk-eIF4E axis (Lam et al., 2014).  
Among several CDK9 inhibitors in the clinical trials, flavopiridol (Alvocidib) is the 
first generation pan-CDK inhibitor with highest potency against CDK9 (Bose et al., 2013). 
Flavopiridol has significant activity in patients with relapsed or refractory chronic 
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lymphocytic leukemia and has received orphan drug designation for treatment of CLL from 
the US FDA. However, its clinical development as therapy has been hampered by a high 
incidence of serious toxicity necessitating inpatient treatment. Nevertheless, its low dose in 
combination with chemotherapy agents found to be effective in a phase II trial of patients 
with advanced colorectal cancer (Aklilu et al., 2003). Dinaciclib is the most advanced CDK9 
inhibitor currently in phase III clinical trials against CLL as a single agent and Phase II 
against different haematologic malignancies as well as some solid tumors. It also inhibits 
multiple CDKs, most notably CDK1, CDK2, CDK5 and CDK9 with IC50 values of 3, 1, 1 
and 4 nM, respectively (Parry et al., 2010) which exhibited superior activity. Phase I dose 
escalation study of dinaciclib in advanced malignancies including majority of colorectal 
cancer patients showed disease stabilization and had better safety profile compared to 
flavopiridol. However, both of these inhibitors suffer from lack of prolonged CDK9 
inhibition due to poor pharmacokinetic properties (Flinn et al., 2005; Gojo et al., 2013). Thus, 
new inhibitors with the improved pharmacological properties are in high demand. 
The current study explored therapeutic potential of CDKI-73, an oral and highly 
potent CDK9 inhibitor, by examining its effect on human colon cancer cell lines (HCCLs) of 
different clinical relevance. CDKI-73 effectively induced apoptosis through the inhibition of 
CDK9 activity which also targeted Mnk-eIF4E signalling as a downstream effect of CDK9 
inhibition. Preclinical xenograft model of HCT 116 human colorectal tumor validated the 
efficacy of CDKI-73 and its CDK9 targeting effect in the tumor confirmed. Based on the 
findings, CDK9 inhibition represents a promising therapeutic approach and CDKI-73 is a 
promising drug candidate for treating colorectal cancer. 
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2. Materials and methods 
2.1. Chemical compounds 
CDKI-73 was synthesized (Shao et al., 2013) and kindly provided by Changzhou LeSun 
Pharmaceuticals Ltd. China. Doxorubicin and flavopiridol were purchased from Sigma-
Aldrich (Castle Hill, Australia). Z-VAD-FMK was purchased from Merck (Kilsyth, 
Australia). All the compounds were dissolved in dimethylsulfoxide (DMSO) at a 
concentration of 10 mM stock and stored at -20 °C. 
2.2. Cell culture 
All HCCLs were obtained from the cell bank at the Centre for Drug Discovery and 
Development, University of South Australia. Cells were cultured in Roswell Park Memorial 
Institute (RPMI)-1640 medium supplemented with 10% fetal bovine serum (FBS) at 37 °C in 
a 5% CO2 atmosphere. 
2.3. Cell viability and caspase-3/7 activity assays  
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (Sigma-Aldrich, Castle 
Hill, Australia) was used to estimate the viability of all HCCLs as reported previously (Wang 
et al., 2004). Concentrations of the compounds required to reduce cell viability by 50% (IC50) 
were calculated using GraphPad Prism 7.02 (La Jolla, California, USA). Caspase-3/7 activity 
was measured using an Apo-ONE homogeneous caspase-3/7 kit (Promega, Madison, WI, 
USA) according to the manufacturers’ instructions and analysed using an EnVision multi-
label plate reader (PerkinElmer, Beaconsfield, UK). 
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2.4. Cell cycle analysis, detection of apoptosis and mitochondrial membrane potential 
(MMP)  
For cell cycle analysis in HCT 116 and HT29 cells, 8 × 10
4
 cells were seeded and incubated 
overnight at 37 °C in a 5% CO2 atmosphere. Following exposure to each compound for 24 h, 
cells were trypsinised and centrifuged (300 × g, 5 min) to collect the cell pellets which were 
then fixed with 70% ethanol on ice for 15 min. Then, centrifuged again to collect the pellets 
and incubated with staining solution (50 μg/mL propidium iodide (PI), 0.1 mg/mL 
ribonuclease A, 0.05% Triton X-100) at 37
 
°C for 1 h followed by analysis using CytoFLEX 
flow cyctometer (Beckman Coulter, Brea, CA, USA). For the detection of apoptosis and 
cellular mitochondrial membrane potentiality (MMP) in HCT 116 cells, annexin V/ PI double 
staining and JC-1 staining methods were followed, respectively. Commercially available 
apoptosis detection kit and MitoScreen (JC-1) kit were purchase from Becton Dickinson, 
NSW, Australia. Following manufacturer’s instruction, samples were analysed using the 
CytoFLEX or Gallios flow cytometer (Beckman Coulter, Brea, CA, USA) within 1 h of 
staining. Data were analysed using CytExpert 2.1 or Kaluza v1.2 softwares (Beckman 
Coulter). 
 
2.5. CDK9 knockdown in HCT 116 and HT29 cells  
For stable knockdown in HCT 116 and HT29 cells, MISSION shRNA clones targeting 
human CDK9 (shCDK9#1: TRCN0000199892, shCDK9#2: TRCN0000000494 and 
shCDK9#3: TRCN0000000497), a pLKO.1-puro empty vector and a non-targeted shRNA 
were used. Plasmids containing shRNA clones and controls were purchased from Sigma-
Aldrich Pty. Ltd.  Following manufacturer’s instruction, the cells were transfected with the 
CDK9 shRNA and control plasmids using Lipofectamine 3000 Reagent (Life Technologies, 
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VIC, Australia). Transfected cells were selected by adding puromycin (1 μg/mL) to the 
culture for two weeks. The relative expression of CDK9 was assessed subsequently by real 
time-quantitative PCR (RT-qPCR) and Western blotting. 
2.6. Western blotting 
Western blotting with cell lysates was performed either following Simple Western
TM
 assays 
(ProteinSimple, Santa Clara, CA, USA) according to manufacturers’ instructions (Rustandi et 
al., 2012) or as previously described (Liu et al., 2012). For xenograft tumor tissues, western 
blot was performed following a modified method described previously (Booher et al., 2014). 
Briefly, the lysates were prepared by sonicating (Qsonica Sonicator, Melville, New York) the 
smashed tumor tissues in 2.5 μL/mg lysis buffer (containing protease and phosphatase 
cocktail inhibitors). Supernatants were collected after centrifuging for 15 min at 13,000 rpm 
at 4°C. Antibodies used were as follows: total RNAPII, phosphorylated RNAPII serine 2 (p-
RNAPII
S2
) and serine 5 (p-RNAPII
S5
) (Covance, NJ, USA), 4E-BP1, p-4E-BP1
T70, β-actin, 
procaspase-3, procaspase-7, CDK9, c-Myc, eIF4E, p-eIF4E
S209
, eIF4G, p-Erk
T202/Y204
, p-
p38
T180/Y182
, p38, rpS6, Mcl-1, Mnk1, PARP, cleaved PARP (Cell Signalling Technology, 
Danvers, MA, USA), Erk
 
(ProteinSimple or Cell Signalling Technology), MDM-2 (Becton 
Dickinson, NSW, Australia), Bcl-2, cyclin D1, p-S6
S240/244
, and p53 (Dako, Glostrup, 
Denmark). Both anti-mouse and anti-rabbit immunoglobulin G horseradish peroxidase 
conjugated antibodies were obtained from Dako (Dako, Glostrup, Denmark). 
2.7. Real time-quantitative PCR (RT-qPCR) 
RNA extraction was performed using the High Pure RNA Isolation Kit (Roche Applied 
Science, Castle Hill, Australia). Using the Transcriptor First Strand cDNA Synthesis Kit 
(Roche Applied Science, Castle Hill, Australia), 1 μg of RNA was used in a 20 μL reverse 
transcription reaction. RT-qPCR was carried out in duplicate with cDNA using SYBR Green 
I dye (Roche Applied Science, Castle Hill, Australia) and performed using a LightCycler
®
 96 
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instrument (Roche Applied Science, Penzberg, Germany). Relative quantification using E-
method established by Roche Applied Science (Tellmann, 2006) was performed with β-Actin 
as reference gene and untreated samples as study calibrators. The sequences of primers and 
amplification efficiency (E) were as follows: β-actin: 5’-ACTCTTCCAGCCTTCCTTC-3’ 
(forward) and 5’-GATGTCCACGTCACACTTC-3’ (reverse), E = 1.72; BCL-2: 5’-
ATGGGATCGTTGCCTTATGC-3’ (forward) and 5’-
CAGTCTACTTCCTCTGTGATGTTGT-3’ (reverse), E = 1.89; CDK9: 5’-
AAAACGAGAAGGAGGGGTTCC-3’ (forward) and 5’-CCTTGCAGCGGTTATAGGGG-
3’ (reverse), E = 1.92; CYCLIN D1: 5’-TTTCTGATGAAATCAGCCCTAGT-3’ (forward) 
and 5’-GCACGGTCAGGTGACACATA-3’ (reverse); E = 1.72; MCL-1: 5’-
AACAAAGAGGCTGGGATGGG-3’ (forward) and 5’-TGCCAAACCAGCTCCTACTC-3’ 
(reverse); E = 1.80; MNK1: 5’-AAGGCCATTGAGACACTTCG-3’(forward) and  5’-
CCCAAATGAAATAAAGCTCCTG-3’ (reverse); 4E-BP1: 5’-
TGACCAAAACACCCCCAAGG-3’ (forward) and 5’-TGTGACTCTTCACCGCCCG-3’ 
(reverse). 
2.8. In vivo studies 
The in vivo studies were conducted following the approved protocol from institutional animal 
ethics committee and approval for the in vivo xenograft study (project number: U15-14) was 
provided by the University of South Australia animal ethics committee (Adelaide, Australia). 
An HCT 116 xenograft model was established as described previously (Lu et al., 2014). 
Briefly, female nude (nu/nu) Balb/C mice at 6 to 8 weeks were inoculated subcutaneously on 
their hind flanks with 2.5 × 10
6
 HCT 116 cells suspended in RPMI medium. Tumor bearing 
mice were randomly allocated into different treatment groups (n=8 mice per group) and the 
treatments were commenced when the average tumor volume reached ~100 mm
3
. CDKI-73 
or vehicle control (5% N-methyl-2-pyrrolidone/95% polyethylene glycol-400) was 
A
cc
ep
te
d 
A
rt
ic
le
Molecular Oncology (2019) © 2019 The Authors. Published by FEBS Press and John Wiley 
& Sons Ltd. 
administered by oral gavage once every three days (Q3D). Cisplatin, the positive control, was 
dissolved in 0.9% normal saline and administered by intraperitoneal injection once per week 
(Q7D). Mice were humanely killed if they reached the clinical endpoint defined by the 
approved protocol (tumor volume ≥2, 000 mm3 or body weight loss ≥15% of the pre-
treatment weight). Tumors from five mice from each group (vehicle and 100 mg/kg CDKI-
73) were collected for western blot analysis and immunohistochemistry (IHC). 
2.9. Immunohistochemistry 
Immunohistochemistry with the tumour tissues collected from xenograft study was performed 
as previously described (Lokman et al., 2013). Briefly, the formalin-fixed tumor tissues were 
processed, embedded in paraffin and then sectioned (5 µm). The tissues are then underwent 
antigen retrieval (5 min 750 W, 15 min 350 W in a microwave) in 10 mM citrate buffer (pH 
6.5). Then the tissues were immunostained with Ki67 (rabbit monoclonal, 1/400, Epitomics, 
CA, USA) as described previously (Ricciardelli et al., 2011). Streptavidin-peroxidise 
conjugate (1/500, Dako) and diaminobenzidine tetrahydrochloride (DAB) (Sigma-Aldrich) 
were used to visualize the staining. Images were recorded using a NanoZoomer Digital 
Pathology System (Hamamatsu Photonics, SZK, Japan).  
 2.10. Statistical analysis 
All the in vitro data presented as mean ± standard deviation (SD) and representative figures 
are provided. Representative graphs or figures are presented from at least three independent 
experiments. In case of in vivo study, the data are presented as mean ± standard error of mean 
(SEM). The statistically significant differences between the groups were analysed by 
appropriate unpaired t- test or one-way ANOVA. All statistical analyses were performed 
using GraphPad Prism 7.03 (La Jolla, California, USA). The significance level was set as p ≤ 
0.05. 
 
A
cc
ep
te
d 
A
rt
ic
le
Molecular Oncology (2019) © 2019 The Authors. Published by FEBS Press and John Wiley 
& Sons Ltd. 
3. Results 
3.1. CDKI-73 potently inhibits the growth and activates caspase-3/7 in HCCLs 
CDKI-73 was identified through structure-guided medicinal chemistry and is one of the most 
potent among existing CDK9 inhibitors (Shao et al., 2013; Walsby et al., 2014). It exhibited 
marked anti-cancer activity against a wide range of cancer cell lines (Lam et al., 2014). To 
determine the cellular potency of CDKI-73 and its effect on the viability of HCCLs, we use a 
panel of four well characterised HCCLs (COLO 205, HCT 116, HT29 and KM12) 
representing different stages of the disease (Huang et al., 2000; Schneider et al., 2012; 
Svingen et al., 2004). CDKI-73 exhibited anti-proliferative activities against all the cell lines 
in a dose and time-dependent manner with IC50 values ranging from 0.017 and 0.972 μM, 
being most potent against HCT 116 (Fig. 1A-D). CDKI-73 potently inhibited the growth of 
HCT 116 cells as early as 24 h with an IC50 value of 0.081 M (flavopiridol, IC50 = 0.068 
M) (Fig. 1B and Supplementary table S1). Prolonged exposure (i.e. 48 and 72 h) to CDKI-
73 caused further reduction in cell viability. 
To investigate the apoptotic mechanism, the activity of caspase-3/7 was measured in 
each HCCL after 24 h exposure to CDKI-73. Flavopiridol was used as a comparator. As 
shown in Fig. 1E, CDKI-73 caused a dose-dependent activation of caspase-3/7 starting from 
0.06 μM concentration and significant levels (p < 0.05) of caspase activation were observed 
at 0.25 and 1 μM concentrations. The different concentrations of CDKI-73 required for 
activation of caspase3/7 in the HCCLs were consistent with the anti-proliferative activities by 
24 h MTT assays (Fig. 1A-D). Flavopiridol exhibited similar profiles in caspase-3/7 
activation on these HCCLs to CDKI-73 (Fig. 1F). 
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3.2. CDKI-73 induces apoptosis without affecting cell cycle  
Our previous studies showed that CDKI-73 also inhibits CDK1 and CDK2 in kinase assays 
(Walsby et al., 2014). Both CDKs have a profound effect on the DNA contents of the cells in 
the respective G1-S and G2-M phase of the cell cycle. Thus, we investigated whether CDKI-
73 and knockdown of CDK9 (CDK9KD) affected the cell cycle distribution of HCT 116 and 
HT29 cells. Fig. 2A shows no detectable accumulation of cells in any particular phase of the 
cycle in HCT 116 and HT29 cells treated with CDKI-73 (0.25 M). Similarly, no significant 
cell cycle arrest was observed in CDK9KD cells except accumulation of cells in Sub-G1 
phase. There was no significant difference between the transfection controls (i.e. empty 
vector and non-target shRNA) and untransfected cells (Figure 2A and Supplementary Fig. 
S1). A substantial increase in sub-G1 population of the both CDKI-73 treated and CDK9KD 
cells indicated the occurrence of cell death. HCT 116 and HT29 cells were treated with either 
a pan-caspase inhibitor Z-VAD-FMK (20 M) or Z-VAD-FMK plus CDKI-73. There were 
no noticeable changes in the percentage of sub-G1 population, suggesting that CDKI-73 can 
induce cell death in a caspase-independent manner which was further confirmed by apoptosis 
analysis.  
 
Further apoptosis analysis utilising annexinV/PI double staining assay revealed that 
0.25 M CDKI-73 induced apoptosis (annexin V +/ PI- and annexin V+/PI+) in ~50% of 
HCT 116 and ~20% of HT29 cells. Co-treatment of CDKI-73 with Z-VAD-FMK resulted in 
a similar trend of apoptotic effect (~39% in HCT 116 and ~18% in HT29 cells) when 
compared to the treatment with CDKI-73 alone (Fig. 2B, C). Taken together, CDKI-73 
induced both caspase-dependent and -independent apoptosis in HCT 116 and HT29 cells. The 
presence of caspases increased the susceptibility (i.e. ~10 % increased apoptosis in HCT 116 
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cells) of cell death driven by the pharmacologic inhibition. Doxorubicin (1 µM) was used as a 
positive control for this experiment. Co-treatment with Z-VAD-FMK significantly reduced 
the doxorubicin induced apoptosis in both HCT 116 (from ~40% to ~20%) and HT29 (from 
~25% to ~12%) cells.  
 3.3.   CDK9 inhibition leads to the loss of mitochondrial integrity in cancer cells 
CDK9 activity in cardiac tissue has been known for its transcriptional suppression of genes 
required for normal mitochondrial function, such as PGC-1α and its downstream effectors, 
resulting in cardiac hypertrophy (Sano et al., 2004; Ventura-Clapier et al., 2008). However, in 
cancer, the role of CDK9 in mitochondrial function has not been elucidated. CDK9 regulates 
the expression of anti-apoptotic proteins like Bcl-2, cyclin D1 and Mcl-1 which play roles in 
mitochondrial function (Hardwick and Soane, 2013; Perciavalle et al., 2012; Sakamaki et al., 
2006). Using RT-qPCR, we showed that transcription of these genes was reduced in HCT 
116 cells after 4 h of exposure to 0.25 μM CDKI-73 or flavopiridol (Fig. 3A). Western 
blotting confirmed that the corresponding protein levels were also reduced (Fig. 3B). Loss of 
mitochondrial membrane potential leading to passage of ions across mitochondria and release 
of cytochrome c into cytoplasm is a distinctive feature of programmed cell death at early 
stage. The effect of CDKI-73 on the mitochondrial membrane potential (MMP) of HCT 116 
cells was assessed by JC-1 assay, which determine the polarity of cellular mitochondria. 
After 48 h of exposure to 0.25 μM CDKI-73 or flavopiridol, the level of MMP in HCT 116 
cells was reduced in a caspase-independent manner (Fig. 3C). Depolarisation of cellular 
mitochondria, initiated through transcriptional inhibition by CDKI-73, presented the cells 
with mitochondria-dependent apoptosis as an alternative mechanism for cell death. 
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3.4. CDKI-73 targets CDK9-mediated transcription leading to down-regulation of 
eIF4E-mediated translation 
Western blot analysis was performed to study the biologic response of CDK9 inhibition by 
CDKI-73 and its mechanism of action in HCT 116 and HT29 cells. CDKI-73 potently 
inhibited the phosphorylation of RNAPII at serine 2 residue (i.e. p-RNAPII
S2
) which is the 
hallmark of CDK9 activity (Natoni et al., 2011). As shown in Fig. 4A, treatment of HCT 116 
and HT29 cells with CDKI-73 for 1 h reduced the level of p-RNAPII
S2
 at 0.25 μM 
concentration and abolished at 1 μM. The level of phosphorylated RNAPII at serine 5 residue 
(i.e. p-RNAPII
S5
) was also reduced but to a much lesser extent. As we previously reported 
that CDKI-73 also inhibits the phosphorylation of eIF4E (Lam et al., 2014), we investigated 
the proteins involved in the Mnk-eIF4E axis and they were not affected after 1 h treatment. 
All these confirm that CDK9 is the primary target of CDKI-73.  
To investigate the downstream effect of pharmacologic inhibition of CDK9 by CDKI-
73, we extended the treatment period to 24 h in both HCT 116 and HT29 cells. 0.25 M 
CDKI-73 resulted in the robust reduction of p-RNAPII
S2
 (Fig. 4B). At 0.25 μM concentration 
CDKI-73 was capable of reducing the expression of Mnk1 and thus blocking the Mnk-
mediated eIF4E phosphorylation at serine 209 (p-eIF4E
S209
) and reduced phosphorylation of 
ribosomal protein S6 (p-S6
Ser240/244
) (Figure 4A and 4E, top and bottom). From Fig. 4F, we 
can see that the effect of CDKI-73 on Mnk1 was at transcription level as the MNK1 mRNA 
was significantly reduced after 0.25 μM treatment. No changes in the levels of RNAPII and 
eIF4E proteins were detected. These observations confirmed that CDKI-73 targeted CDK9-
mediated transcription of proteins involved in the translational regulation in HCT 116 and 
HT29 cells. 
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We further investigated the effect of CDKI-73 on the MAPK and mTOR pathways. 
The activity of Mnk1 is regulated by p38 mitogen-activated protein kinase (p38 MAPK) and 
extracellular signal-regulated kinases (Erks) through phosphorylation at T209/214 (Scheper 
et al., 2001; Waskiewicz et al., 1997). Western blot analysis of HCT 116 and HT29 cells after 
24 h exposure to CDKI-73 showed minimal effect on the Erk and its phosphorylation (Fig. 
4C). p38 MAPK is activated by mitogen-activated protein kinase MKK 3/6 through 
phosphorylation at T180 and Y182 residues (p-p38
T180/Y182
). Again, CDKI-73 did not affect 
the expression levels of p38 and p-p38
T180/Y182
. However, the phosphorylation of eIF4E 
binding protein 1 (4E-BP1) i.e. p-4E-BP1
T70
 was reduced by 0.25 M CDKI-73 and 
decreased levels of 4E-BP1 and ribosomal protein S6 (rpS6) proteins were also observed. The 
mRNA level of 4E-BP1 was also reduced but was not statistically significant (Fig. 4F). 
Recently, we demonstrated that CDKI-73 causes apoptosis through reduction of Mcl-
1 and c-Myc in MLL-AML cell lines (Li et al., 2015). Mcl-1 and c-Myc are known to be 
regulated by CDK9-driven transcription and eIF4E-mediated translation (Hou et al., 2012; 
Wang and Fischer, 2008). As shown in Fig. 4D, the expressions of Mcl-1 and c-Myc were 
inhibited in HCT 116 cells after treatment with 0.25 μM CDKI-73. The same treatment also 
suppressed the level of cyclin D1 protein. The induction of cleaved caspase-3 and -7 
confirmed the occurrence of apoptosis. Consistent with our previous studies with other CDK9 
inhibitors (Liu et al., 2012; Wang et al., 2010), the treatment with increasing concentrations 
of CDKI-73  led to progressive increases in p53 in HCT 116 cells, and this was accompanied 
by reductions in MDM2 protein, a short-lived protein responsible for the ubiquitination of 
p53 (Fig. 4D). However, we could not detect expression of wild-type p53 in HT29 cells as it 
is a p53 mutated cell line (Ahmed et al., 2013). 
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3.5. Knockdown assay confirms the CDK9 targeted mechanism of CDKI-73 and 
involvement of CDK9 in eIF4E signalling 
shRNA-mediated knockdown assay was performed to confirm the CDK9 targeted mechanism 
of CDKI-73. Among three CDK9-targeted shRNA clones, about 80% knockdown of CDK9 
was achieved in HCT 116 and HT29 cells using shCDK9#2 and shCDK9#3 when compared 
to untreated and shRNA controls (empty vector and non-target) (Fig. 5A, B). Notably, CDK9 
knockdown conferred resistance to CDKI-73 in HCT 116 and HT29 cells (by more than 100-
fold and 10-fold, respectively) for at least 24 h treatment (24h, IC50 > 10 M; Supplementary 
Table S1). Treatment of CDK9
 
knockdown (CDK9KD#2 and CDK9KD#3) HCT 116 and 
HT29 cells with 10 M CDKI-73 over a period of 0 to 72 h revealed that CDKI-73 was 
significantly less potent against those cells (p < 0.05) compared to 1 M CDKI-73 treated 
wild-type HCT 116 (Fig. 5C, top) and HT29 (Fig. 5C, bottom) cells. Cells transfected with 
empty vector and non-target shRNA also showed similar level of sensitivity compared to the 
wild-type cells. The resistance to CDKI-73 treatment in CDK9KD cells compared to wild-
type cells provided evidence of its CDK9 targeted mechanism. Moreover, knockdown of 
CDK9 caused apoptosis in HCT 116 and HT29 cells, whereas, empty vector and non-targeted 
shRNA did not cause any apoptosis (Fig. 5D). To understand whether that the reduction of 
eIF4E-mediated translation by CDKI-73 was driven by its inhibition of CDK9, we 
investigated the effect of CDK9 knockdown on Mnk-eIF4E pathways in CDK9KD HCT 116 
and CDK9KD HT29 cells compared to untransfected cells and shRNA controls (empty vector 
and non-target). The protein levels of CDK9, p-RNAPII
S2
 and p-eIF4E
S209
 were reduced in 
the CDK9KD cells (Fig. 5E). Consistent with our previous finding in A2780 ovarian cancer 
cell line, CDK9 knockdown did not affect the Mnk1 protein in HCT 116 cells. However, 
Mnk1 was slightly reduced in CDK9KD HT29 cells.  
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The CDK9KD cells also showed a reduction in p-Erk
T202/Y204 
without affecting the 
Erk protein (Fig. 5E), suggesting a role of CDK9 on eIF4E-Mnk mediated translation. The 
expression of 4E-BP1 and rpS6, and their phosphorylation were influenced by the 
knockdown CDK9. This indicated a downstream effect of CDK9 knockdown on the 
translation pathway. However, only the phosphorylation of p38 (p-p38
Thr202/Tyr204
) was 
reduced, but the total p38 remained unaffected.  CDK9 knockdown also had an effect on the 
expression levels of c-myc, cyclin D1, cleaved caspase-7 and PARP (Fig. 5E) correlating 
with the apoptotic effect shown in the CDK9KD HCT 116 and CDK9KD HT29 cells (Fig. 
5D).  
3.6. CDKI-73 suppresses the growth of colorectal tumor by targeting CDK9 in vivo 
The greater advantage of CDKI-73 over the clinical experimental CDK9 inhibitors i.e.  
flavopiridol and dinaciclib, is its excellent drug property with high oral bioavailability which 
made its possible to be orally administrable to patients. We confirmed the therapeutic 
efficacy of CDKI-73 in an HCT 116 xenograft model. As shown in Fig. 6A, HCT 116 tumor 
bearing animals treated with 100 mg/kg CDKI-73 orally once every 3 days caused a 
significant tumor growth inhibition (p < 0.05) from day 11 onwards when compared with the 
vehicle group. Cisplatin was also efficacious compared to the vehicle. CDKI-73 showed 
significant inhibition of tumor growth when compared to cisplatin on day 17 (p ≤ 0.05). 
Further treatment with CDKI-73 resulted in markedly reduction in the tumor volumes by day 
19 (Fig. 6B, p < 0.001). There was no significant body weight loss or other clinical signs of 
toxicity in CDKI-73 treated mice (Fig. 6C). 
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Furthermore, we have investigated the in vivo mechanism of tumor growth inhibition by 
utilising western blot and immunohistochemistry (IHC) analysis of the tumors collected from 
the xenografted animal treated with CDKI-73 or vehicle (n=5). The treatment with CDKI-73 
caused robust reduction of p-RNAPII
S2
 confirming inhibition of CDK9 kinase activity. In 
line with our in vitro findings, CDKI-73 also reduced the level of Mcl-1 and Bcl-2, which 
was accompanied by induction of apoptosis indicated by cleavage of PARP when compared 
to the vehicle treated tumors (Fig. 6D). IHC analysis of these tumor tissues exhibited that 
CDKI-73 markedly reduces the proliferation as indicated by significantly decreased in level 
of Ki-67 positive cells (Fig. 6E and F, p < 0.001). 
 
4. Discussion 
CDK9 is highly expressed in CRC (Uhlen et al., 2015). Promising in vitro targeting profile of 
CDKI-73 against a wide range of cancer cell lines and its low toxicity towards normal cells 
have led to this current study. In consistent with our previous findings (Lam et al., 2014; 
Walsby et al., 2014), CDKI-73 manifested potent anti-proliferative effects against all HCCLs 
tested, irrespective of the cellular characteristics, e.g. histopathology, differentiation, and 
clinical stage of disease. As IC50 value is correlated to cell doubling time, time-dependent 
sensitivity to CDKI-73 was consistent with the previously reported doubling time of the 
HCCLs tested (Bazzocco et al., 2015; Dahlmann, 2013). Having the shortest doubling time 
compared to the other cell lines, HCT 116 was the most sensitive to CDKI-73 treatment from 
24 h and onwards. Cellular CDK9 targeting specificity of CDKI-73 was demonstrated by 
comparing its effect in wild-type and CDK9KD (HCT 116 and HT29) cells. As CDK9KD 
cells already have a reduced level of CDK9 activity accompanied by reduced level of anti-
apoptotic proteins (Mcl-1, c-Myc and cyclin D1; Fig. 5E), they were less sensitive than the 
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cells expressing CDK9 (Fig. 5C and Supplementary table S1). CDKI-73 reduced the 
phosphorylation of RNAPII (i.e. p-RNAPII
S2
, Fig. 4A) supporting to the notion that CDKI-73 
primarily targets CDK9. 
CDKI-73 also reduced cellular Mnk activity (Fig. 4B) and thus suppressed the eIF4E-
mediated translation. As p-eIF4E found to be elevated in CRC (Diab et al., 2014), this 
additional inhibitory effect might contribute to the rapid induction of apoptosis in HCT 116 
cells. The role of CDK9 in the Mnk-eIF4E axis was confirmed by the simultaneous reduction 
of p-RNAPII
S2
 and the Mnk activating kinases (i.e. p-Erk
T202/Y204
) in the CDK9KD cells, as 
shown in Fig. 5E. Although Erk phosphorylation was reduced in CDK9KD cells, it was 
barely affected by pharmacologic inhibition via CDKI-73 (Fig. 4C, 5E). While the underlying 
cause remains to be elucidated, a previous study has implicated a role of Erk in the assembly 
of P-TEFb by stabilising CDK9 (Fujita et al., 2008). The reduced level of p-Erk
T202/Y204
 could 
be due to the downregulation of CDK9 associated genomic network in the CDK9KD cells. 
Clearly, there is discrepancy between pharmacological inhibition and gene silencing. CDKI-
73 blocks the function of CDK9 but the protein is still present, whereas shRNA removed 
CDK9 mRNA and its protein from the cell, consequently affecting the network of genes and 
proteins that associated with CDK9, including Mnk-eIF4E axis.  
Cell cycle analysis of HCT 116 and HT29 cells treated with CDKI-73 showed 
substantial cell death (i.e. Sub-G1 cell populations, Fig. 2A), which was confirmed by the 
detection of apoptotic cells as shown in Fig. 2B. CDKI-73 retained the ability in inducing 
apoptosis in the presence of a pan-caspase inhibitor Z-VAD-FMK, suggesting it can cause 
caspase-independent apoptosis. One plausible explanation is that CDKI-73 inhibits the 
transcription of key genes for mitochondria function such as Mcl-1 that plays an essential role 
in the maintenance of membrane stability (Gojo et al., 2002; Minagawa et al., 2005). 
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In addition to their oncogenic properties, Bcl-2, cyclin D1 and Mcl-1 play a role in 
mitochondrial function and stability (Harris and Thompson, 2000; Minagawa et al., 2005; 
Sakamaki et al., 2006). Our previous studies have shown that CDKI-73 induced apoptosis by 
targeting short-lived pro-survival mRNAs, such as MCL-1, XIAP and BCL-2 in cancer cells 
(Lam et al., 2014; Walsby et al., 2014). Thus, transcriptional repression of these factors leads 
to depolarisation of mitochondrial membrane which results in the release of apoptogenic 
factors including apoptosis-inducing factor and endonuclease G triggering caspase-
independent apoptosis (Kroemer et al., 2007). Consistent with previous report that 
flavopiridol caused early mitochondria damage and induced caspase-independent apoptosis 
through the transcription inhibition of Mcl-1 (Hussain et al., 2008), CDKI-73 inhibited Mcl-1 
at both mRNA and protein levels (Fig. 3A, B). However, the reduction of cyclin D1 at 
mRNA level was not as prominent as the reduction at protein level. The combined effect of 
downregulation of transcription and eIF4E-mediated translation caused by CDK9 inhibition 
might have led to such striking effect at cyclin D1 protein level. Furthermore, in line with our 
previous findings (Lam et al., 2014; Liu et al., 2012), CDKI-73 elevated the level of p53 with 
a concomitant reduction in MDM2 (Fig. 4D). Interestingly, CDKI-73 also caused apoptosis 
through simultaneous inhibition of Mcl-1, c-Myc and cyclin D1 in the p53 mutated HT29 
cells (Fig. 4D). 
Oral administration of CDKI-73 demonstrated an excellent anti-tumor efficacy in a 
HCT 116 xenograft model (Fig. 6A, B). While they seemed sharing the similar mechanism of 
action in vitro, CDKI-73 has an advantage of better pharmacokinetics and higher oral 
bioavailability than flavopiridol. Moreover, the dose limiting toxicity due to lack of 
selectivity and prolonged CDK9 inhibition narrowed the therapeutic index of flavopiridol 
(Dey et al., 2017; Lanasa et al., 2015), whereas CDKI-73 has shown a remarkably reduction 
of toxicity in non-cancerous cells (Walsby et al., 2014). The western blot analysis of the 
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tumors collected from xenografted mice treated with CDKI-73 confirmed its inhibition of 
CDK9 in vivo (Fig. 5E). The treatment resulted in the reduction of known CDK9 targets i.e. 
Bcl-2 and Mcl-1 in tumor tissues. In addition to that, significantly lower Ki-67 proliferative 
index (Fig. 6F, p < 0.001) predicted increased survival in CDKI-73 treated mice (Oshima et 
al., 2005). These findings emphasise the therapeutic potential of CDKI-73 for treatment of 
CRC. 
5. Conclusions 
We have identified CDKI-73 as a highly potent anti-proliferative agent against HCCLs. 
CDKI-73 effectively induced cancer cell death and displayed a robust CDK9 targeted 
mechanism of action both in vitro and in vivo. It downregulates multiple anti-apoptotic 
factors and inhibited tumor growth of the HCT 116 xenograft by oral administration. The 
high potency and low toxicity make CDKI-73 a highly attractive candidate for development 
towards the clinic. 
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Supporting information 
Additional Supporting Information may be found online in the supporting information section 
at the end of the article. 
Supplementary Table S1. Time-course anti-proliferative effect of CDKI-73 on wild-type and 
CDK9 knockdown HCT 116 and HT29 cells determined by MTT assays. 
Supplementary Fig. S1: Cell cycle analysis in CDK9 knockdown cells. 
 
Figure legends: 
Fig. 1. Growth inhibitory profile of CDKI-73 against HCCLs. (A-D) Representative dose 
response curves for the Colo 205, HCT 116, HT29 and KM12 cells after treatment with 
CDKI-73 for indicated time points. IC50 values are shown. Caspase-3/7 activity in HCCLs 
following the treatment with (E) CDKI-73 or (F) flavopiridol for 24 h. Data represent the 
mean ± SD of at least three independent experiments. * denotes statistical significance (p ≤ 
0.05) compared with untreated control determined using unpaired t- test. 
Fig. 2. Induction of apoptosis by CDKI-73 in HCT 116 and HT29 cells. (A) Cell cycle 
analysis of HCT 116 and HT29 cells after exposure to 0.25 M CDKI-73 for 24 h. (B) 
Apoptosis analysis of HCT 116 and HT29 cells after incubation with CDKI-73 for 48 h by 
annexin V/PI assay. Co-treatment of CDKI-73 with Z-VAD-FMK (20 μM) was performed to 
demonstrate the caspase independency. Representative cytometric plots are presented. (C) 
Quantification of apoptotic cells. Untreated cells were used ass negative control. Doxorubicin 
(Dox, 1 µM) was used as positive control. Data presented as mean ± SEM of three 
independent experiments. Ten thousand events were recorded for each treatment condition 
and cellular debris was excluded from the analysis. * denotes p < 0.05 compared with 
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negative control; # denotes p < 0.05 compared with respective treatment without Z-VAD-
FMK determined by ANOVA followed by Student Newman-Keuls test. 
Fig. 3. Inhibition of CDK9 reduced mitochondrial membrane potential. (A) RT-qPCR 
showed relative mRNA levels of BCL-2, CYCLIN D1 and MCL-1 in HCT 116 cells after 
exposure to CDKI-73 or flavopiridol for 4 h, normalized against β-actin. Data presented as 
mean ± SD of three independent experiments; * denotes p ≤ 0.05, ** denotes p ≤ 0.01, *** 
denotes p ≤ 0.001 (unpaired t-test). (B) Western blot analysis of the cells after treatment with 
CDKI-73 or flavopiridol for 24 h. (C) Cellular MMP was determined by JC-1 assay in HCT 
116 cells after 48 h treatment with CDKI-73 or flavopiridol. Co-treatment with Z-VAD-FMK 
(20 μM) was performed to demonstrate the caspase independency. 
Fig. 4. Cellular mode of action of CDKI-73. (A) Western blot analysis after 1 h treatment of 
HCT 116 and HT29 cells with CDKI-73 at different concentrations. (B-D) Western blot 
analysis showing downstream effects of CDKI-73 on Mnk/eIF4E-mediated translational 
pathway in HCT 116 and HT29 cells after 24 h treatment. β-Actin was used as an internal 
loading control. (E) Bar graph showing relative amount of p-eIF4E
Ser209
 and p-S6
Ser240/244
 in 
HCT 116 (top) and HT29 (bottom) (normalized to loading control, mean ± SD, n=3). (F) RT-
qPCR showing the relative mRNA levels of MNK1 and 4E-BP1 after 4 h treatment with 0.25 
M CDKI-73. β-actin was used as a reference gene. * denotes p ≤ 0.05 (unpaired t-test). 
Fig. 5. Effects of CDK9 knockdown in CRC cells. (A) Comparison of CDK9 expression in 
wild-type and knockdown HCT 116 cells at protein level (top) and Relative at mRNA level 
(bottom). of CDK9 in shRNA-mediated CDK9KD HCT 116 cells. (B) Comparison of CDK9 
expression in wild-type and knockdown HT29 cells at protein level (top) and at mRNA level 
(bottom). CDK9 expression levels of the empty vector and non-target shRNA controls are 
also shown.Western blot showing CDK9 expression in CDK9KD HCT116 cells. (C) 
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Viability of CDK9KD HCT 116 and wild-type HCT 116 (HCT 116; top and HT29; bottom) 
cells after treatment with indicated concentration of CDKI-73 over a period of 0 to 72 h. Data 
shown as mean ± SD, n = 3, * denotes p < 0.05, unpaired t-test. (D) Apoptosis analysis in 
CDK9KD cells. Empty vector and non-target shRNA controls are also shown. Representative 
figures are shown from at least two independently repeated experiments. (E) Western blot 
analysis of HCT 116 and HT29 cells transfected with CDK9 shRNA. Untransfected cells, 
cells transfected with empty vector and non-target shRNA were used as controls. Effects of 
CDK9KD on Mnk/eIF4E-mediated translational pathway of these cells were determined 
using the indicated antibodies. Proteins involved in the apoptotic pathways such as Mcl-1, 
cyclin D1, c-myc, cleaved caspase-7 and cleaved PARP were also examined. β-Actin was 
used as an internal loading control.  
Fig. 6. In vivo anti-tumor efficacy of CDKI-73 in HCT 116 xenograft model. Groups of 8 
animals were administered with vehicle, cisplatin (4 mg/kg, IP, Q7D) or CDKI-73 (100 
mg/kg, PO, Q3D). (A) Graph showing tumor volume at different days in group of mice 
receiving specific treatment (mean ± SEM).* denotes p < 0.05 (one-way ANOVA). (B) 
Scatter plot showing comparison and individual tumor volume among the three groups on 
day 19 (horizontal line indicates the means while vertical lines indicate standard deviations). 
One-way ANOVA was used to determine statistical .significance. (C) Graph showing body 
weight loss in different groups. (D) Western blot analysis of tumor tissues collected from the 
xenograft studies. GAPDH was used as a loading control. (E) IHC analysis for proliferative 
activity (Ki67) in HCT 116 xenograft tumor tissues (scale bar, 50 µm). (F) Five fields were 
randomly selected from each tissue (from five mice in each group) for quantitation of 
proliferative index. Data represent as the mean ± SEM. Unpaired t-test was used to determine 
the p values. 
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